DMARDs for RA Improve Vascular Inflammation and CV Risk : co

Receipt of a tumor necrosis factor inhibitor or triple therapy for rheumatoid arthritis yielded an equally beneficial effect for reducing vascular inflammation and cardiovascular risk.

Related Keywords

Boston , Massachusetts , United States , Canada , Toronto , Ontario , , Amgen , Women College Hospital , National Institute Of Arthritis , Medscape Medical , Rheumatic Diseases , Medscape Medical News , Lihi Eder , College Hospital , National Institute , Rheumatoid Arthritis , A , Cv , Ardiovascular , Arthritis , Oint Inflammation , Disease Modifying Antirheumatic Drugs Dmards , Mard Disease Modifying Antirheumatic Drug , Tumor , Adherence , Dherence To Medication Issues For Patients , Hospitals , Scan , Biologic Therapy , Arteries , Cardiovascular Disease , Vd Cardiovascular Disease , Interleukins , Monoclonal Antibody , Etuximab , Ituximab , Spain , Statin , Ipid Low ,